ZSHK Laboratories
ZSHK Laboratories Limited is a biopharmaceutical pre-clinical research and development service company dedicated to providing comprehensive research services including pharmacology, pharmacodynamics, pharmacokinetics, safety evaluation, and other related services for pharmaceutical companies and R&D organizations worldwide. The company has established independent laboratories in Hong Kong, Shenzhen, and Suzhou, and has built breeding and scientific research bases for experimental animals, supporting the development and registration of new drugs and medical devices. It offers a wide range of services including early pharmacodynamics screening, pharmacokinetics, safety evaluation, disease models, and more, with advanced evaluation platforms and a professional team.
Industries
Nr. of Employees
medium (51-250)
ZSHK Laboratories
Hong Kong Special Administrative Region Shatin District Science Park Room 330, Block E, No. 16 West of Science and Technology Avenue
Products
Preclinical Research and Evaluation Services
Provides preclinical research and evaluation services for drugs and medical devices, including pharmacology, pharmacodynamics, pharmacokinetics, and toxicology studies.
Early Pharmacodynamics Screening
Offers early drugability evaluation to assess pharmacodynamics, pharmacokinetics, and safety of lead molecules, aiding in the selection of potential drug candidates.
Test Systems
Provides a variety of animal models for pharmacodynamics studies, including non-human primates, rodents, and non-rodents, to support preclinical research.
Drug Safety Testing Center
Operates a drug safety testing center in Hong Kong Science Park, offering toxicology, genotoxicity, toxicokinetics, safety pharmacology, and reproductive toxicology services.
Experimental Animal Breeding and Research
Maintains breeding and research bases for experimental dogs and non-human primates in Hunan and Guangxi to support preclinical studies.
Preclinical Research and Evaluation Services
Provides preclinical research and evaluation services for drugs and medical devices, including pharmacology, pharmacodynamics, pharmacokinetics, and toxicology studies.
Early Pharmacodynamics Screening
Offers early drugability evaluation to assess pharmacodynamics, pharmacokinetics, and safety of lead molecules, aiding in the selection of potential drug candidates.
Test Systems
Provides a variety of animal models for pharmacodynamics studies, including non-human primates, rodents, and non-rodents, to support preclinical research.
Drug Safety Testing Center
Operates a drug safety testing center in Hong Kong Science Park, offering toxicology, genotoxicity, toxicokinetics, safety pharmacology, and reproductive toxicology services.
Experimental Animal Breeding and Research
Maintains breeding and research bases for experimental dogs and non-human primates in Hunan and Guangxi to support preclinical studies.
Services
In vitro and in vivo early-stage evaluation of pharmacodynamics, pharmacokinetics and safety to assess candidate druggability, including genotoxicity, local toxicity and safety pharmacology panels.
Comprehensive in vitro ADME assays and in vivo PK/ADME studies including plasma kinetics, tissue distribution, excretion, mass balance and modality-specific PK evaluation.
Design and execution of pharmacodynamic studies, establishment and validation of disease models across oncology, respiratory, metabolic, neurological, immune, renal and cardiovascular systems, and integration with PK and safety endpoints.
GLP-style safety evaluation services including single/repeat dose toxicology, safety pharmacology, local toxicity and reproductive/genotoxicity endpoints tailored for regulatory submissions.
Clinical pathology and laboratory analysis services including hematology, blood chemistry, coagulation, urinalysis, immunoglobulin/complement assays, cytokine detection and platelet/coagulation factor testing.
Tissue processing and histopathological examination including paraffin and frozen section handling and special staining for pathological assessment.
In vitro and in vivo early-stage evaluation of pharmacodynamics, pharmacokinetics and safety to assess candidate druggability, including genotoxicity, local toxicity and safety pharmacology panels.
Comprehensive in vitro ADME assays and in vivo PK/ADME studies including plasma kinetics, tissue distribution, excretion, mass balance and modality-specific PK evaluation.
Design and execution of pharmacodynamic studies, establishment and validation of disease models across oncology, respiratory, metabolic, neurological, immune, renal and cardiovascular systems, and integration with PK and safety endpoints.
GLP-style safety evaluation services including single/repeat dose toxicology, safety pharmacology, local toxicity and reproductive/genotoxicity endpoints tailored for regulatory submissions.
Clinical pathology and laboratory analysis services including hematology, blood chemistry, coagulation, urinalysis, immunoglobulin/complement assays, cytokine detection and platelet/coagulation factor testing.
Tissue processing and histopathological examination including paraffin and frozen section handling and special staining for pathological assessment.
Expertise Areas
- Preclinical safety evaluation
- Pharmacokinetics and ADME
- Pharmacodynamics and disease-model development
- Bioanalysis for small and large molecules
Key Technologies
- High-performance liquid chromatography (HPLC)
- Flow cytometry / immunophenotyping
- CYP450 inhibition and induction assays
- Microsomal and hepatocyte metabolic stability assays
News & Updates
On May 5, 2022, ZSHK Laboratories Limited was approved for membership of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), enhancing its industry collaboration and development.
On May 16, 2022, ZSHK's CEO Dr. Li Ming visited HKAPI in Hong Kong to discuss biopharmaceutical research and development collaboration, and opportunities for industry development.
Management team of ZSHK visited HKAPI office to discuss collaboration and industry development.
The President of Hong Kong Biotechnology and Medical Industry Association visited ZSHK for collaboration discussions.
AnLing (Shenzhen) received full accreditation from AAALAC, demonstrating high standards in animal research facilities.
On May 5, 2022, ZSHK Laboratories Limited was approved for membership of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), enhancing its industry collaboration and development.
On May 16, 2022, ZSHK's CEO Dr. Li Ming visited HKAPI in Hong Kong to discuss biopharmaceutical research and development collaboration, and opportunities for industry development.
Management team of ZSHK visited HKAPI office to discuss collaboration and industry development.
The President of Hong Kong Biotechnology and Medical Industry Association visited ZSHK for collaboration discussions.
AnLing (Shenzhen) received full accreditation from AAALAC, demonstrating high standards in animal research facilities.